Chromatan Receives a Phase IIB SBIR award from the NIH

April 2022

We are very happy to announce that Chromatan has been awarded the Phase IIB SBIR award from the NIH for $2,000,000. The funds will be used over the next 2 years to launch the CCTC platform to market and scale the platform cGMP as well as to develop a fully integrated process for antibody manufacturing via perfusion reactor and CCTC.

Chromatan signs a major R&D contract with Takeda for long-term investigation of CCTC for Blood Plasma Purification. The work will be performed at our headquarters

March 2022

Chromatan completes all milestones and receives renumeration totaling $2.3 Million from the FDA for the development of the integrated downstream bioprocess for monoclonal antibodies.

ChromaTan receives a subaward from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL).

January 2022

ChromaTan receives a subaward from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The project involves the utilization of the CCTC platform for washing protein precipitates produced as an alternative to column-based antibody capture. The project is led by Rensselaer University, Penn State and several major industry sponsors such as Takeda, Millipore Sigma, and Astrazeneca.

Chromatan completes delivery of our first sales order of the CCTC system to MIT as part of the $750,000 project sponsored by the Massachusetts Life Sciences Center

December 2021

Chromatan Receives US patent approval for next generation CCTC “Continuous countercurrent spiral chromatography.”

September 2021

Chromatan Receives US patent approval for next generation CCTC “Continuous countercurrent spiral chromatography”. Please see link below. This newest innovation from our team will be used extensively for long term processes and gene therapy applications.
US11110374B2 - Continuous Countercurrent Spiral Chromatography

Chromatan Completes all milestones with the FDA

September 2021

Chromatan completes all milestones and receives renumeration totaling $2.3 Million from the FDA for the development of the integrated downstream bioprocess for monoclonal antibodies.

ChromaTan Completes Series A Fundraising Efforts For $2.1 Million

January 2021

We are excited to announce completion of our Series A round. We had a coalition of investors that included individual angels, super angel groups, strategic investors and Ben Franklin of Southeastern PA. Thank you all for believing in us!

ChromaTan Partners With Proconex

October 2020

We are very excited to announce a new strategic partnership with Proconex – a member of Emerson Impact Partner Networks.

Proconex is a world-class market leading supplier of Emerson DeltaV process automation solutions. Proconex has invested both and cash and in-kind in ChromaTan’s Series A. Our teams are jointly working on the implementation of a complete automation solution for the CCTC platform based on DeltaV.

$600,000 Award From NIIMBL!

February 2020

We are very excited to announce the reception of a $600,000 award from NIIMBL for the development of next generation CCTC.

The 1-year project to commercialize our next generation platform involves a cooperative project agreement with the computation fluid dynamics team from Penn State under the leadership of Dr. Ali Borhan. The project is also supported by Genentech and Merck which will provide testing material, scale up support, and analytical expertise.

This work is performed under a Project Award Agreement from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award 70NANB17H002 from the U.S. Department of Commerce, National Institute of Standards and Technology.

Over 50% Of The $3M Series A Equity Round Raised!

January 2020

We are very happy to announce that ChromaTan has now raised over 50% of the $3 Million Series A equity round.

$1.57 Million has now been raised from several angel investor groups and individuals that include Lehigh Valley Angels, Social Venture Circle, Mid-Atlantic Diamond Ventures, and Sorensen Family office.

For more information on the round please contact Oleg Shinkazh, CEO at

CEO Oleg Shinkazh Interviewed By Biostrategy Forum

January 2020

CEO Oleg Shinkazh was interviewed by Biostrategy Forum. The conversation centered around strategic partnerships, investor relations, and customer acquisition.

New Paper Published In Partnership With Merck!

November 2019

We are thrilled to announce a publication of a landmark paper in partnership with Merck titled “Improved protein A resin for antibody capture in a continuous countercurrent tangential chromatography system”.

The paper features the highest ever recorded productivity in a resin-based Protein A capture process of 140 grams of mAb/ Liter of resin / hr. We would also like to thank our partners from Purolite Life Sciences for working with on innovating a new type of small particle agarose resin that enabled such high process efficiencies.

New Patent Published!

June 2019

We would like to announce a publication of our new patent titled “High efficiency continuous countercurrent tangential chromatography”.

The patent features a significant improvement of the flow path design for the CCTC platform and extends our exclusivity by 5 years to 2034!

Partnership With MIT And Takeda!

May 2019

We are very happy to announce a partnership with MIT and Takeda on a 2-year $750,000 contract awarded by the Massachusetts Life Sciences Center

The award will sponsor a sale of our first commercial CCTC pilot system as well as support an extensive evaluation of the platform by Takeda. The work will be performed at the newly created continuous bioprocessing center at MIT under the leadership of Dr. Richard Braatz. The group at MIT will be working with the Chromatan team on creating a detailed dynamic modeling tool designed for extensive characterization of the CCTC platform for integrated continuous bioprocessing.

ChromaTan Graduates From Incubation!

April 2019

We have now moved into a newly renovated facility in Springhouse Innovation Park! The facility for completely renovated for our needs and will serve as our new corporate headquarters and demonstration facility for the CCTC platform!

This wonderful innovation park is located about 35 min North-West of Philadelphia and is also the home of the Jefferson Institute of Bioprocessing (JIB) which opened its doors in September 2019.

ChromaTan Is Sponsoring The CCP Summit In Boston On Continuous Bioprocessing

January 2019

Read the interview with CEO Oleg Shinkazh about the advantage and challenges of Continuous Bioprocessing for Biologics, click here to download the PDF.

The event is being held at the Hyatt Regency Hotel January 29th – 31st.

Please come visit our booth and talk at 12:30 pm ET on January 30th.

Click here for full event details.

ChromaTan Wins An Investor Pitch Competition At The Comcast Center In Philadelphia!

November 2018

Our reward is a guaranteed entrance to PACT 2019, one of the most prestigious venture conferences PACT in 2019!

Winner’s badge below:

Norman Sorensen And Son Erik Sorensen Invest $200,000 In A Convertible Bridge Into ChromaTan And Pledge $150,000 More Towards Series A

November 2018

Norman Sorensen is Former Chairman, President & CEO of Principal International, the global business holding company of Principal Financial Group (Nasdaq: PFG), where from 1998 through 2012 he was responsible for managing over $120 Billion in pension, retirement, annuities, mutual funds and asset management businesses with over 10 million customers in 12 countries.

A Quote from Norman on the attractiveness of ChromaTan as an investment opportunity is below:

 “My base notion about investing in ChromaTan has been the understanding that the population of the US and other developed nations around the world is rapidly aging because of the baby boomers generation. This is happening at such a rate that it's no longer acceptable for governments to be in the position to continue to defray entitlement costs of Medicare and Medicaid going forward. Some measures have to be taken before these programs inevitably go bankrupt. There are only two ways to solve this - to decrease costs through innovation and/or cutting entitlements.

Development and drug manufacturing are major costs, and methods of production are antiquated. ChromaTan's innovation is a very compelling message by elegantly addressing a major challenge for biologics production. I think the company could become an important contributor to helping solve the crisis of healthcare costs which in my opinion is a major “civilization challenge” that must be tackled.”

Interested Investors - please inquire with CEO Oleg Shinkazh at 

ChromaTan and PendoTECH Co-Publish A White Paper On The Utilization Of In-Line Sensors In Continuous Processing In Bioprocess International

October 2018

To read the white paper, click here [PDF].

ChromaTan Signs A $100,000 R&D Contract With Largest Biopharma In The World – Roche

October 2018

Roche and ChromaTan have signed a $100,000 R&D contract. The purpose of the work is to demonstrate the capabilities of the CCTC platform as applied to a commercial antibody-based therapy in Roche’s pipeline. An extensive letter of support has been executed by Wolfgang Koehnlein, who is the lead of the project from Roche. Please contact ChromaTan to request the letter.

NIH Supplements ChromaTan With $255,000 Award!

September 2018

ChromaTan receives an additional award for $255,000 from the NIH to supplement its current Phase II $1.5M NIH SBIR grant! The award will fund the supplemental equipment necessary to accomplish the integration of CCTC with the perfusion bioreactor into a single continuous unit operation!

Applikon Biotechnology And ChromaTan Co-Publish A White Paper On The Development On The Integrated Continuous And Single-Use Bioproduction Platform (ICS)

September 2018

The paper explores the optimization of Perfusion and Cell separation device (Biosep) and outlines data collected during the Phase I portion of the NIH grant award.

To read click here [PDF].

GEN Magazine Features Two Articles That Discuss The ChromaTan Platform!

GEN Magazine Features Two Articles That Discuss The ChromaTan Platform!

September 2018

Recent edition of Genetic Engineering & Biotechnology News (GEN) journal features both articles in a special edition entitled, “Continuous Bioprocessing: Brave Old Challenges with Bold New Technologies”. ChromaTan’s (CCTC) platform was highlighted in the articles below:

Visions of a Continuous Bioprocess Future” by Josh Roberts

Continuous Processing’s Benefits within Biopharma’s Reach” by Applikon’s Erik Kakes

Bioprocessing Summit Booth & Presentation

August 2018

At the Bioprocessing Summit 2018, ChromaTan shared an exhibitor’s booth with Purolite, one of the world’s largest manufacturers of chromatography media in the world.

Dmitriy Fedorenko – our Associate Director of Process Sciences presented a technical talk entitled, “Paving the Way to integrated Continuous Bioprocessing: In-line PAT for Steady-State Purification with the CCTC Platform”.

ChromaTan Presents At The BIO Conference

June 2018

ChromaTan hosted an exhibition booth in the “Emerging Innovators Zone” at the BIO 2018 conference held in Boston with CEO Oleg Shinkazh presenting a 10-min pitch on the company and its platform.

ChromaTan Receives The Numera System With Lucullus Software Licenses From Partner Securecell

June 2018

ChromaTan and Securecell are partnering to introduce Securecell’s state-of-the-art Lucullus software solution and the Numera in-line sampling platform to be integrated into the ChromaTan’s continuous bioprocessing solutions for process control and in-line sample prep and analysis. The software solution will power the CCTC system and provide a single interface across all involved devices. The Numera system will provide in-line sampling for the multiple unit operations and closes the links between the bioprocesses and the necessary reference analytics. The combination of both enables advanced monitoring and process control along the whole process chain.

BPI Europe – ChromaTan CEO Oleg Shinkazh Presents The ChromaTan Platform To European Audiences

April 2018

The joint presentation with partners Purolite drew a substantial crowd!

ChromaTan And University of Maryland Are Awarded $600,000 From NIIMBL

March 2018

The award will be used to develop in-line NMR instrument for measurements of protein concentration and aggregation. This is the very first award in the history of NIIMBL. For more details on the award click for press release here.

September 25th–28th 2017 – Bioprocess International (BPI) Showcase In Boston, MA

September 2017


AT BOOTH 1323!

Oleg Shinkazh, CEO of ChromaTan will be giving a featured talk at 2:30 p.m. on Wed September 27th on development and implementation of end-to-end continuous bioprocessing. He will be joined by Purolite's Application Manager Hans Johannson.

On the conference floor we will be featuring the beta version of our Process Development CCTC system.

Our partner Purolite Life Sciences will be joining us at BPI to showcase our new resin, jetting, and bioprocess technologies. Please read about our partnership at this link (PDF).

ChromaTan opens a new location in Philadelphia Science Center!

August 2017

The company will be performing all laboratory and business functions out of this new location while the engineering department completes design and construction of the Process Development CCTC system in State College, PA.

ChromaTan, Eli Lilly, and Penn State publish a seminal paper in Journal of Chromatography A after a long-term R&D collaboration!

July 2017

The work showcases fantastic results of applying the CCTC platform to mixed-mode polishing chromatography.

Read article here: Continuous countercurrent tangential chromatography for mixed mode post-capture operations in monoclonal antibody purification

ChromaTan and Purolite Corporation execute a strategic collaboration on chromatography resin development that resulted in an innovative new resin product that was specifically designed for the CCTC platform. Click the link below to read the announcement!

June 2017


ChromaTan receives a $500,000 infusion of capital from Life Science Greenhouse of Central PA and invites their portfolio manager Steve Carpenter to the company board!

April 2017

ChromaTan receives a $100,000 infusion of capital from Blue Tree Venture Partners.

April 2017

ChromaTan grows the company headcount to 7 empoyees by hiring Bill Muzika as a Controls Engineer and Jonathan Walko as an Associate Engineer.

January 2017

ChromaTan completes the Phase I milestones for the Fast Track Phase II SBIR, gaining access to $1.5 Million in funds over the next two years to complete the Integrated Continuous and Single-Use bioproduction platform.

December 2016

ChromaTan publishes a peer reviewed publication in Biotechnology Progress.

March 2016

The paper is focused on detailed discussion of performance optimization of the CCTC platform for antibody capture.

Read publication here: Performance optimization of continuous countercurrent tangential chromatography for antibody capture

ChromaTan received a $1.73 Million Fast-Track Phase II SBIR grant award for the development of ICS – Integrated Continuous and Single-use bio-production platform. The development efforts over the next 3 years will focus on integrating CTC technology with perfusion bioreactors resulting in the first of its kind single-use platform for producing and purifying biologics in a continuous manner.

January 2016

ChromaTan received technology endorsement from three of our future customers MedImmune / Astrazeneca, Regeneron, and NRC Canada. The letters describe our testing efforts and lay out intentions for further commercialization and sales of CCTC technology. One of the letters is attached, click here to view!

ChromaTan welcomes Dr. Soroosh Soltani and Dmitriy Fedorenko to our team, taking our head count to 6! These additions will significantly strengthen ChromaTan’s technical group with talent and expertise in both upstream and downstream processing!

ChromaTan raises additional $170,000 of convertible debt from new investors!

September 2015

ChromaTan is featured in GEN magazine company profile!

August 2015

Read article here: ChromaTan Purifies against the Current

ChromaTan files a PCT patent for new claims on CTC system improvements, additional operational modes and methods!

May 2015

ChromaTan publishes a landmark peer reviewed paper in the special addition of the Journal of Biotechnology on Continuous processing.

March 2015

This publication was more than 1 year in the making, and involved collaborations and co-authorships from Penn State University, Fujifilm Diosynth, and Regeneron!

Read publication here: Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography

ChromaTan is featured in GEN magazine’s Bioprocessing Perspective!

March 2015

Click here to read the article.

ChromaTan submits a major publication to Journal of Biotechnology. The paper is co-written with Penn State, Fujifilm Diosynth and Regeneron Pharmaceuticals.

November 2014

ChromaTan completes the CTC demo system and starts the ChromaTan blitz - a technology demonstration campaign with our first early adoption candidate.

November 2014

ChromaTan receives additional funding from NIH on the Phase II extension for $175,000!

October 2014

ChromaTan presented data that was jointly generated with Fujifilm Diosynth and Regeneron Pharmaceuticals at several industry conferences including Prep, Recovery, ManuBio and Bioprocess International.

June - October 2014

ChromaTan presented data that was jointly generated with Fujifilm Diosynth and Regeneron Pharmaceuticals at several industry conferences including Prep, Recovery, ManuBio and Bioprocess International. The results showed 4-5 times productivity increase over the status quo technology with comparable purity and yield. The data causes significant excitement in the industry and leads to several technology evaluation requests from major antibody manufacturers.

ChromaTan was awarded Phase II funding from the National Institute of Helath (NIH) for $985,000! This is a major milestone for our team and serves as a major validation for all the hard work that our team has been doing!

October 2013

Some excerpts from the summary review statements:

"... This Phase II project has high significance because it describes a way to more cheaply purify proteins on large scale as needed for biopharmaceutical production. The innovation is high because the basic concept of the chromatography is new and appears to offer significant advantages"

".... This is an exciting prospect for those that depend on the production of such compounds. This is highly significant"

"... The CCTC system is a novel approach to using selective resins, like Protein A, in the purification of large amounts of protein. The resin is efficiently used unlike a conventional column where much of the column is “waiting” for the sample. This is clever engineering."

ChromaTan was recently awarded an investment of $225,000 from Ben Franklin Technology Partners of Central PA! The funds will be used to boost the development of CCTC and increase ChromaTan's headcount to five!

July 2013

ChromaTan and ASI have been featured on Pharmaceutical Technology in the article entitled "Single-Use Continuous Chromatography Overcoming Limitations of Traditional Protein Purification" by Dr. Cynthia Challener. Below is a short blurb:

Continuous countercurrent tangential chromatography combines the principles of chromatography and continuous/conveyor-belt processing with liquid–liquid extraction and tangential flow filtration to create the first “true moving bed” technology (as opposed to simulated moving bed) that is capable of large-scale, column-free capture purification of biologics, according to Shinkazh.

Initially developed by Chromatan and now under joint development by Chromatan and ASI, the Evopure system preserves the robust resin interaction and buffer chemistry of column chromatography while using a flow path specifically designed for single-use operation.

The Evopure system addresses three critical needs of the purification industry—cost savings on capital and operational costs, a single-use and sterile flow path, and linear scalability, according to Smeltz. Specifically, with CCTC, throughput is increased 5- to 10-fold when compared to conventional columns, which enables high resin cycling in a single batch. CCTC thus, makes single-use capture practical and introduces significant cost savings of up to 65% to the end user, according to Shinkazh.

Click Here To Read More

May 2013

ChromaTan publishes "Continuous Countercurrent Tangential Chromatography for Monoclonal Antibody Purification", a landmark paper in Separation Science and Technology!

April 2013

In-Pharma technologist highlights ChromaTan's partnership with ASI with exclusive podcast interview of ASI's president Kent Smeltz and ChromaTan's CEO Oleg Shinkazh! Click here to listen to the podcast (Internet Explorer is recommended).

June 2012

ChromaTan closes the seed round at $560,815 by raising $227,815 from angel investors, friends and family!

February 2012

ChromaTan featured in Centre Daily Times news article "Programs, Grants Help Boost Business"!

January 2012

ChromaTan welcomes our new VP of engineering Boris Napadensky!

ChromaTan moves into new office and laboratory space in the wonderful technology incubator at 200 Innovation park in State College, PA

December 2011

ChromaTan is funded by Ben Franklin Technology Partners of Central PA with a $150,000 debt investment!

ChromaTan signs a material transfer agreement with FujiFilm Diosynth.

October 2011

ChromaTan hires Dr. Achyuta Teella to begin work on the continuous CTC prototype system! Welcome aboard!

September 2011

ChromaTan received an Phase 1 SBIR Award from the National Institute of Health (NIH) for $183,000 to construct a pilot Countercurrent Tangential Chromatography system!

August 2011

ChromaTan's Countercurrent Tangential Chromatography Methods, Systems, And Apparatus patent has been issued! You may download a PDF copy of the patent from the Intellectual Property section for review.

May 2011

ChromaTan's Continuous Countercurrent Tangential Chromatography System patent has been issued! You may download a PDF copy of the patent from the Intellectual Property section for review.

March 2011

ChromaTan's article titled 'Countercurrent tangential chromatography for large-scale protein purification' has been published in Volume 108, Issue 3 March 2011 of Biotechnology and Bioengineering.

July 2010

ChromaTan advances to the finals of Masschallenge! Masschallenge is a competition for startup companies.

ChromaTan will be moving into the accelerator stage of the program for a chance to win $100,000 dollars! More details at

March 2010

ChromaTan wins funding grant from Ben Franklin Technology Partners.

Spectrum is now an investor in ChromaTan.

January 2010

Getting Real with Downstream ProcessingGEN

"Like all areas of bioprocessing, downstream purification has its own favored buzzwords—titers, bottlenecks, capacity, and others—meant to evoke a particular response depending on who is speaking or writing them. But, if we could just identify one leading, universal trend in downstream bioprocessing, it would be simplification."


December 2009

The ChromaTan team successfully created an innovative solution in countercurrent chromatography at the Penn State University Fenske Laboratory based on a patent pending design.

Feasibility studies completed - BSA/Myoglobin separation, excellent recovery, purity and hydrodynamic stability achieved.

August 2009

Partnership with Penn State and Dr. Andrew Zydney established.

March 2009

Patent filed.

January 2009

ChromaTan is officially incorporated.

Interested in learning more about our protein purification solutions?

Call or email us to learn more about system performance, applications, integration, and case studies.